Format

Send to

Choose Destination
Methods Mol Biol. 2019;1911:481-503. doi: 10.1007/978-1-4939-8976-8_33.

Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies.

Author information

1
Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
2
School of Medicine, Tsinghua University, Beijing, China.
3
Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ, USA. aploss@princeton.edu.

Abstract

In spite of the immense progress in hepatitis C virus (HCV) research, efforts to prevent infection, such as generating a vaccine, have not yet been successful. The high price tag associated with current treatment options for chronic infection and the spike in new infections concurrent with growing opioid abuse are strong motivators for developing effective immunization and understanding neutralizing antibodies' role in preventing infection. Humanized mice-both human liver chimeras as well as genetically humanized models-are important platforms for testing both possible vaccine candidates as well as antibody-based therapies. This chapter details the variety of ways humanized mouse technology can be employed in pursuit of learning how HCV infection can be prevented.

KEYWORDS:

Hepatitis C virus; Humanized mice; Immunization; Neutralizing antibodies

PMID:
30593647
DOI:
10.1007/978-1-4939-8976-8_33
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center